UFH

DRUG3 trials

Sponsors

Sanofi, Bayer, VarmX B.V.

Conditions

Acute Coronary SyndromeCardiovascular DiseaseCoagulation DisorderCoronary Artery Disease

Phase 1

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Active, not recruitingNCT06517563

VarmX B.V.Coagulation Disorder

Start: 2024-08-14End: 2026-10-31Target: 16Updated: 2025-09-10

Phase 2

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

CompletedNCT01442792

BayerCardiovascular Disease, Coronary Artery Disease

Start: 2011-10-12End: 2013-03-04Updated: 2022-06-23

Phase 3

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

CompletedNCT01076764

SanofiAcute Coronary Syndrome

Start: 2010-04-30End: 2013-05-31Updated: 2016-05-04

Related Papers

Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.

2021-01-293 citations

Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2021-01-0111 citations

Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors

Circulation Cardiovascular Interventions2018-06-018 citations

Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes

JAMA2013-09-0165 citations